Asimov vs ConcertAI
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mammalian Cell Engineering Platform for Biologics & Gene Therapy
Asimov develops software and AI tools for mammalian cell engineering to accelerate design and manufacturing of biologics and gene therapies; combines synthetic biology, biophysical simulation, and machine learning;
About
Asimov is a Boston-based biotechnology and computational biology company founded in 2017 by Alec Nielsen, Raja Srinivas, and Christopher Voigt. The company's mission is to apply software engineering principles to cell engineering — treating genetic circuits in mammalian cells the way software engineers treat code. Asimov builds computational tools and AI models that predict how genetic constructs will behave in mammalian cells, enabling researchers to design, simulate, and optimize biologics and gene therapy vectors before conducting expensive wet lab experiments.
ConcertAI is an oncology AI and real-world data company at a $1.9B valuation — 5.5M multi-modal cancer RWD records, $230M+ raised, exiting FY2024 profitable with mid-teens EBITDA margins.
About
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates multi-modal patient data — including electronic health records, genomics, imaging, and pathology — from a network of oncology providers to support biopharma companies in clinical trial design, site selection, protocol optimization, patient matching, and regulatory submission.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.